The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

Serena Williams' suggestion that injectable weight loss drugs could have helped her in tennis is part of an ongoing ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Today, we're diving into a hot topic in the world of health and wellness: semaglutide. You might have heard about this medication in the context of weight loss. While it's a promising tool, it's ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...